A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

A regiszterben nem jelölt feltételek

• All Cohorts Inclusion Criteria:
• Willing and able to participate in the research and provide biospecimens
• Willing and able to provide informed consent
  • Cohort 001 Inclusion:
• Have documented diagnosis of AML according to the World Health Organization (WHO) classification
• Secondary AML is allowed
  • Cohort 002 Inclusion:
• Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
• Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
• 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
• 002B (Newly Diagnosed, High Risk): Intended for first line treatment
• 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)
• 002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
• 002D (Transformed FL): Pathologically confirmed transformation
  • All Cohorts Exclusion Criteria:
• Not willing or able to adhere with the study procedures
  • Cohort 001:
• Have received any prior therapy intended for standard of care (SoC) treatment of AML
  • Cohort 002:
• 002A: Received prior treatment for follicular lymphoma
• 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
• 002A: Resected patients with NED
• 002B: Intended for active observation
• 002B: Received prior treatment for follicular lymphoma